Skip to main content

Twist Bioscience Corporation (TWST) Stock Analysis

Oversold Bounce setup

SellModerate Confidence

Healthcare · Diagnostics & Research

Sell if holding. Engine safety override at $49.12: Quality below floor (3.3 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.9/10. Specifically: High short interest: 29%; Below-average business quality.

Twist Bioscience manufactures synthetic DNA and NGS tools using a proprietary silicon chip-based synthesis platform, serving 3,800+ customers in healthcare ($215.1M), chemicals/materials ($93.2M), academic research ($65.9M), and food/agriculture markets. FY2025 revenue was... Read more

$49.12+12.1% A.UpsideScore 4.9/10#23 of 26 Diagnostics & Research
QualityF-score6 / 9FCF yield-1.91%
Stop $46.56Target $55.10(analyst − 13%)A.R:R 0.9:1
Analyst target$63.33+28.9%9 analysts
$55.10our TP
$49.12price
$63.33mean
$36
$75

Sell if holding. Engine safety override at $49.12: Quality below floor (3.3 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.9/10. Specifically: High short interest: 29%; Below-average business quality. Chart setup: Oversold RSI 27, near Bollinger lower, volume surge. Score 4.9/10, moderate confidence.

Passes 6/8 gates (clean insider activity, no SEC red flags, news events none recent, earnings proximity 78d clear, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum and favorable risk/reward ratio. Suitability: aggressive.

Val5.7Qual3.3Grw7.3Mom4.3Sent7.6Ins3.3Peer2.3Tech7.8Risk2.44.9OVERALL

Recent Developments — Twist Bioscience Corporation

Latest news

Generated 2026-05-20T20:21:22Z.

Thesis

Rewards
No bull case signals
Risks
Concentration risk — Supplier: single-source supplier for critical DNA synthesis component
Quality below floor (3.3 < 4.0)

Key Metrics

P/E (TTM)—
P/E (Fwd)-24.0
Mkt Cap$3.1B
EV/EBITDA-27.3
Profit Mgn-19.8%
ROE-18.2%
Rev Growth19.3%
Beta2.23
DividendNone
Rating analysts16

Quality Signals

Piotroski F6/9MoatNarrow

Concentration Risks(10-K Item 1A)

  • HIGHSuppliersingle-source supplier for critical DNA synthesis component
    10-K Item 1A: 'We depend on one single-source supplier for a critical component for our DNA synthesis process.'

Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer

Rating Breakdown

3 floor-breakers

Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static

Quality Rank
0.6
Value Rank
2.3
Growth Rank
6.2

Volatile — 6.9% daily ATR makes tight stops impractical. Position-size conservatively.static

Days To Cover
0.0
Volatility
0.0
Short Interest
0.6
Beta
2.6
Debt Equity
9.0
High short interest justified: 29%Concentration risks: 1 HIGH (10-K Item 1A — sized via position_sizing, validated via buy_confidence)

Unprofitable operations — net margin -19.8%. Quality floor flags this regardless of sector context.static

Roe
0.0
Roa
0.0
Operating Margin
0.0
Net Margin
0.0
Fcf Quality
0.0
Gross Margin
6.4
Piotroski F
6.7
Moat
7.2
Current Ratio
9.1
Cash-burning: FCF -14% of revenue
GatesMomentum 4.3<4.5A.R:R 0.9 < 1.5@spotInsider activity: OKNo SEC red flagsNEWS EVENTS NONE RECENTEARNINGS PROXIMITY 78d clearSEMI CYCLE PEAK CLEARMATERIALS CYCLE PEAK CLEAROversold BounceSuitability: Aggressive
RSI
27 · Oversold
↓ 20D MA↓ 50D MA↑ 200D MAGOLDEN CROSSSupport $48.00Resistance $66.06

Price Targets

$47
$55
A.Upside+12.2%
A.R:R0.9:1

Position Sizing

ConvictionNone
Suggested %0.5%
Max %1%
RegimeSteady

Risk Alerts

! Quality below floor (3.3 < 4.0)
! Momentum score 4.3/10 — below 4.5 minimum
! Reward/Risk 0.9:1 at current price — below 1.5:1 minimum

Earnings

B
B
B
M
3/4 beats
Next Earnings2026-08-03 (78d)

Verdict History

reverse chrono — latest first
Loading history...
Verdicts are recorded on every nightly pipeline run. Rows capture transitions (verdict flips, score deltas ≥0.3, entry/TP/SL changes). Rows with a ▶ can be expanded to see the change reason. Aggregate cohort performance is tracked in the recommendation ledger.
Frequently Asked Questions
Is TWST stock a buy right now?

Sell if holding. Engine safety override at $49.12: Quality below floor (3.3 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.9/10. Specifically: High short interest: 29%; Below-average business quality. Chart setup: Oversold RSI 27, near Bollinger lower, volume surge. Prior stop was $46.56. Score 4.9/10, moderate confidence.

What is the TWST stock price target?

Take-profit target: $55.10 (+12.1% upside). Prior stop was $46.56. Stop-loss: $46.56.

What are the risks of investing in TWST?

Concentration risk — Supplier: single-source supplier for critical DNA synthesis component; Quality below floor (3.3 < 4.0).

Is TWST overvalued or undervalued?

Twist Bioscience Corporation trades at a P/E of N/A (forward -24.0). TrendMatrix value score: 5.7/10. Verdict: Sell.

What do analysts say about TWST?

16 analysts cover TWST with a consensus score of 4.3/5. Average price target: $63.

What does Twist Bioscience Corporation do?Twist Bioscience manufactures synthetic DNA and NGS tools using a proprietary silicon chip-based synthesis platform,...

Twist Bioscience manufactures synthetic DNA and NGS tools using a proprietary silicon chip-based synthesis platform, serving 3,800+ customers in healthcare ($215.1M), chemicals/materials ($93.2M), academic research ($65.9M), and food/agriculture markets. FY2025 revenue was $376.6M across synthetic biology tools, NGS kits, and biopharma antibody discovery services.

Related stocks: VCYT (Veracyte, Inc.) · BLLN (BillionToOne, Inc.) · SHC (Sotera Health Company) · MEDP (Medpace Holdings, Inc.) · NTRA (Natera, Inc.)